Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camsirubicin with Prophylactic Pegfilgrastim in Advanced Soft Tissue Sarcomas
NCT05043649Phase 1Terminated
- Sponsor
- Monopar Therapeutics Inc.
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camsirubicin in soft tissue sarcoma (STS), sponsored by Monopar Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Recommended Phase 2 Dose at 1 year. Started Sep 2021; status: terminated.
02
Drugs
camsirubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05043649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043649.